Prolia is a prescription medicine used to treat osteoporosis in women
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
Subscribe To Our Newsletter & Stay Updated